An AMC pilot will incentivise makers to produce vaccines for the world's poorest countries
Pneumococcal diseases kill more than 1.6 million people worldwide each year, including at least 800,000 children. Ninety-nine percent of these deaths occur in the world's poorest countries. The most effective way to prevent these deaths is to ensure children have access to effective, safe and affordable vaccines.
The pilot Advance Market Commitment (AMC) is designed to protect children and save lives. Through donor commitments, this innovative funding mechanism incentivises vaccine makers to produce vaccines for the world's poorest countries. These countries are then able to plan for immunization programs knowing that vaccines will be available rapidly, in the quantities they need and at affordable prices.
Work is underway to determine the optimal terms for a pilot AMC. In April, the AMC partners provided a series of briefings for developing countries, manufacturers, civil society organizations and to update stakeholders on the process to date and some of the key considerations.
The donors also asked a group of health and economic experts and implementing agencies, called the Implementation Working Group (IWG), to provide recommendations for AMC terms, building on the work of the Independent Economic Expert Group (EEG).
The IWG received inputs from developing countries, industry, civil society organizations and donors to inform their work. Donors met with the IWG in May and were briefed on progress. Work continues and donors will provide an update in June.
The donors would like to express their appreciation to those who have informed this work. Throughout the development of the AMC, input has been sought and received from hundreds of stakeholders; these diverse perspectives have been of great value.